Stockscreener 앱 받기
9.43
0.32%
0.03
전일 마감가:
$9.40
열려 있는:
$9.315
하루 거래량:
1.74M
Relative Volume:
0.93
시가총액:
$1.59B
수익:
$68.56M
순이익/손실:
$-437.99M
주가수익비율:
-2.9805
EPS:
-3.1639
순현금흐름:
$-396.61M
1주 성능:
-5.32%
1개월 성능:
+1.40%
6개월 성능:
+55.61%
1년 성능:
+71.77%
1일 변동 폭
$9.22
$9.64
1주일 범위
$9.12
$9.91
52주 변동 폭
$4.155
$11.66
비르 바이오테크 Stock (VIR) Company Profile
명칭
Vir Biotechnology Inc
전화
415-906-4324
주소
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.43 | 1.59B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
비르 바이오테크 Stock (VIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | 개시 | Evercore ISI | Outperform |
| 2025-08-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-03-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-02-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 개시 | SVB Leerink | Outperform |
| 2022-09-09 | 개시 | Morgan Stanley | Underweight |
| 2022-03-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-01-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-09-14 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 개시 | Needham | Buy |
| 2020-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-02-27 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 개시 | Robert W. Baird | Neutral |
| 2019-11-05 | 개시 | Barclays | Overweight |
| 2019-11-05 | 개시 | Cowen | Outperform |
| 2019-11-05 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | JP Morgan | Overweight |
모두보기
비르 바이오테크 주식(VIR)의 최신 뉴스
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
VIR stock reacts to latest clinical updates and cash position - ad-hoc-news.de
Vir Biotechnology nears key trial results in he... - Pluang
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead (NASDAQ:VIR) - Seeking Alpha
Hillsdale Investment Management Inc. Invests $1.44 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Discipline and Rules-Based Execution in VIR Response - Stock Traders Daily
Vir Biotechnology, Inc. $VIR Shares Bought by Candriam S.C.A. - MarketBeat
Y Intercept Hong Kong Ltd Takes Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (VIR) BofA Securities 2025 Healthcare Conference Summary - Quartr
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely? - Moomoo
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $16 to $30 - Moomoo
Vir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SA - MarketBeat
VIRVir Biotechnology Inc Latest SEC Filings - Finviz
OP Asset Management Ltd Takes Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Form 144 Vir Biotechnology For: 29 June By Investing.com - Investing.com South Africa
Why Is Vir Biotechnology (NASDAQ:VIR) Turning Heads In Small-Caps? - Kalkine Media
[144] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Enterprise value to EBIT forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Price to sales forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Price to book forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Enterprise value to revenue forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Price to earnings forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Vir Biotechnology, Inc. Actuals & Estimates (NASDAQ:VIR) - TradingView
VIR Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Vir Biotechnology Inc (VIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vir Biotechnology Inc (VIR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biotech executives convene under Vir Biotechnology leadership to drive innovation at BIO2026 - Traders Union
Vir Biotechnology (NASDAQ:VIR) Draws Attention Amid Pipeline Focus - Kalkine Media
Vir Biotechnology Inc (VIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology Inc (VIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vir Biotechnology Inc (VIR) Institutional Confidence - TradingKey
Vir Biotechnology (VIR) Holds Near Support Amid Modest UptickVolatility Smirk - dars.gov.et
Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vir Biotechnology Inc (VIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - AOL.com
VIR Should I Buy - Intellectia AI
VIR Maintained by Morgan Stanley -- Price Target Raised to $27 - GuruFocus
Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00 - MarketBeat
Vir Biotechnology, Inc. Stock 12‑Month Price Target Raised to $21.56, Implies 161% Upside - TradingView
Vir Biotechnology Adds Timothy Coughlin to Board, Audit Chair - The Globe and Mail
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors - BioSpace
Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants - Stock Titan
Vir Biotechnology (VIR) director Coughlin reports zero share ownership - Stock Titan
Vir Biotechnology appoints Timothy Coughlin to board - Investing.com UK
Vir Biotechnology appoints Timothy Coughlin to board By Investing.com - Investing.com South Africa
비르 바이오테크 (VIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
비르 바이오테크 주식 (VIR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Napolitano Janet | Director |
Jun 01 '26 |
Sale |
9.45 |
3,200 |
30,240 |
21,216 |
| Sabatini Brent | SVP, Chief Accounting Officer |
Jun 01 '26 |
Sale |
9.45 |
379 |
3,582 |
61,902 |
0.80%
2.11%
자본화:
|
볼륨(24시간):